Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › belatacept

belatacept

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of belatacept

24 trials tracked of belatacept: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 91 citations.

24Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 8 Phase 3 2 Phase 2 12 Phase 1 2
  1. Phase 3 A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Completed · 91 cited
  2. Phase 4 Belatacept Early Steroid Withdrawal Trial Completed · 33 cited
  3. Phase 4 Bela 8 Week Dosing Completed · 19 cited
  4. Phase 4 Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309) Completed · 5 cited
  5. Phase 4 Efficacy of Belatacept in Reducing DSA Completed
  6. Phase 4 Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients Completed
Show 18 more trials
  1. Phase 4 Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients Completed
  2. Phase 4 Belatacept 3 Month Post Transplant Conversion Study Completed
  3. Phase 4 Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers Completed
  4. Phase 3 Belatacept Therapy for the Failing Renal Allograft Completed
  5. Phase 2 Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Completed
  6. Phase 2 Treg Modulation With CD28 and IL-6 Receptor Antagonists Completed
  7. Phase 2 A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant Completed
  8. Phase 2 Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients Completed
  9. Phase 2 A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation Completed
  10. Phase 2 A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids Completed
  11. Phase 2 Belatacept Conversion in Proteinuric Kidney Transplant Recipients Completed
  12. Phase 2 Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney Completed
  13. Phase 2 Regimen Optimization Study Completed
  14. Phase 2 Islet Transplantation Using Abatacept Completed
  15. Phase 2 Belatacept Post Depletional Repopulation to Facilitate Tolerance Completed
  16. Phase 2 Belatacept Pharmacokinetic Trial in Renal Transplantation Completed
  17. Phase 1 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept) Completed
  18. Phase 1 Subcutaneous Pharmacokinetics of Belatacept Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation
Orthopedics & Sports Medicine Guideline
Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation New Drug Strategies Aim to Stop Your Body From Rejecting a Transplant
This scoping review examines immunosuppressive strategies for solid organ transplant patients, including conventional, biologic, and emergin…
New drug strategies aim to stop your body from attacking a new organ, protecting transplants longer while reducing dangerous side effects fr…
Frontiers Apr 20, 2026
Phase 2a trial of dazodalibep plus belatacept shows 25% acute rejection rate in kidney transplant patients
Nephrology Phase II
Phase 2a trial of dazodalibep plus belatacept shows 25% acute rejection rate in kidney transplant patients Early study tests two-drug combination to prevent kidney transplant rejection
A phase 2a, open-label, single-arm trial in 23 adults undergoing first kidney transplants evaluated dazodalibep plus belatacept as sole main…
A new two-drug kidney treatment was safe but failed to prevent rejection in most patients during this early study.
Apr 5, 2026